Janssen (United Kingdom)

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. Janssen (Belgium)比利时2
2. Merck Serono S.A. (Switzerland)瑞士1
3. GlaxoSmithKline (United Kingdom)英国1
4. Tongji Hospital中国1
5. Janssen Research & Development (United States)美国1
6. Azienda Ospedaliera Universitaria Pisana意大利1
7. London School of Economics and Political Science英国1
8. Janssen Pharmaceutical K.K. (Japan)日本1

按月发文

逐年被引

最新文献

1. 1
   Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United StatesBMC Public Health202440
2. 2
   The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to < 18 YearsDrug Safety20201
3. 3
   Pattern of Onset and Risk Factors for Peripheral Oedema During Vildagliptin Use: Analysis from the Vildagliptin Prescription–Event Monitoring Study in EnglandDrug Safety20162
4. 4
   Recommendations for benefit–risk assessment methodologies and visual representationsPharmacoepidemiology and Drug Safety201678

高被引文献

1. 1
   Recommendations for benefit–risk assessment methodologies and visual representationsPharmacoepidemiology and Drug Safety201678
2. 2
   Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United StatesBMC Public Health202440
3. 3
   Pattern of Onset and Risk Factors for Peripheral Oedema During Vildagliptin Use: Analysis from the Vildagliptin Prescription–Event Monitoring Study in EnglandDrug Safety20162
4. 4
   The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to < 18 YearsDrug Safety20201

主要发表期刊